Cotreatment with growth hormone, after pituitary suppression, for ovarian stimulation in in vitro fertilization: a randomized, double-blind, placebo-control trial.
OBJECTIVE
To explore the effect of cotreatment with growth hormone (GH) for ovarian stimulation after pituitary suppression.


METHODS
A randomized, double-blind, placebo-controlled study.


METHODS
Specialist Reproductive Endocrine and In Vitro Fertilization (IVF) Unit.


METHODS
Twenty-five IVF patients who had responded suboptimally in a previous treatment cycle. A subgroup of 18 patients were found to have ultrasound (US) findings of polycystic ovaries (PCO).


METHODS
The amount of gonadotropin used, development of follicles greater than or equal to 14 mm, number of oocytes collected, fertilized, cleaved and replaced, serum and follicular fluid (FF) insulin-like growth factor I (IGF-I) concentrations.


RESULTS
Cotreatment with GH was associated with a significant reduction in gonadotropins requirement (P less than 0.05). In patients with US-diagnosed PCO more follicles developed (P less than 0.05), more oocytes were collected (P less than 0.03), fertilized (P less than 0.004), and cleaved (P less than 0.02). A significantly higher FF IGF-I concentrations were found in patients receiving cotreatment with GH compared with those who received placebo (P less than 0.04).


CONCLUSIONS
We believe that there may be a place for GH treatment in selected IVF cycles after pituitary suppression but what the role of IGF-I should further be investigated.
Owen
E J
EJ
Cobbold Laboratories, University College and Middlesex School of Medicine, Middlesex Hospital, London, United Kingdom.
Shoham
Z
Z
Mason
B A
BA
Ostergaard
H
H
Jacobs
H S
HS
D000328:Adult; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005307:Fertilization in Vitro; D015571:Follicular Fluid / Q000378:metabolism; D013006:Growth Hormone / Q000494:pharmacology*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008596:Menotropins / Q000627:therapeutic use*; D010053:Ovary / Q000503:physiopathology*; D010902:Pituitary Gland / Q000187:drug effects* / Q000503:physiopathology; D010919:Placebos; D011085:Polycystic Ovary Syndrome / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology; D011247:Pregnancy; D011256:Pregnancy Outcome; D014463:Ultrasonography
D010919:Placebos; D008596:Menotropins; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone